Canavan Disease
Also known as: Aspartoacylase Deficiency, ASPA Deficiency, Van Bogaert-Bertrand Disease
Canavan disease is a rare, progressive, inherited neurological disorder characterized by the spongy degeneration of the white matter (myelin) in the brain. It is caused by a deficiency of the enzyme aspartoacylase, which leads to a buildup of N-acetyl-L-aspartic acid (NAA) in the brain. This accumulation disrupts normal brain development and function.
Canavan disease is a rare brain problem where a part of the brain called myelin doesn't grow right. It makes it hard for kids to move, see, and learn. Doctors are trying to find better ways to help them.
Signs & Symptoms
- Hypotonia (poor muscle tone)
- Developmental delay
- Macrocephaly (abnormally large head)
- Irritability
- Feeding difficulties
- Seizures
- Vision loss
- Progressive loss of motor skills
- Intellectual disability
Treatment Options
Supportive Care
SUPPORTIVEPhysical Therapy
MODERATELY EFFECTIVEOccupational Therapy
MODERATELY EFFECTIVESpeech Therapy
MODERATELY EFFECTIVEMedications for Seizures
MODERATELY EFFECTIVEGene Therapy
EXPERIMENTALDiagnosis
- MRI of the brain (showing characteristic white matter changes)
- Urine test (detecting elevated levels of N-acetyl-L-aspartic acid)
- Blood test (detecting aspartoacylase enzyme deficiency)
- Genetic testing (identifying mutations in the ASPA gene)
History
Canavan disease was first described by Myrtelle Canavan in 1931, who identified the characteristic spongy degeneration of the brain in affected individuals. The genetic basis of the disease was later elucidated, leading to improved diagnostic and potential therapeutic strategies.
Recent Breakthroughs
Gene Therapy Shows Promise in Early-Phase Trials
Early-phase clinical trials of gene therapy for Canavan disease have demonstrated some improvements in motor function and developmental milestones in treated patients. Further research is ongoing to assess long-term efficacy and safety.